原创力文档- 1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
- 2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
- 4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
- 5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传，每下载1次， 网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
•综 述•
肠道菌群失调介导酒精性肝病发生发展的机制研究进展 ························································· 1
•药物警戒•
欧盟建议采取措施降低含羟嗪药物的心脏疾病风险································································· 6
加拿大限制利培酮适应症············································································································ 7
加拿大警示磺胺甲噁唑甲氧苄啶的药物性免疫性血小板减少风险 ········································· 7
加拿大发布达比加群酯与决奈达隆、胺碘酮药物相互作用的安全性审查结果 ······················ 8
新西兰警示唑来膦酸的肌腱损伤／肌腱炎潜在风险································································· 9
欧盟发布《个案病例安全报告实施指南》 ·············································································· 10
加拿大暂停含欧绵马成分顺势疗法产品许可证········································································11
欧盟拟采取措施降低 SGLT2 抑制剂的酮症酸中毒风险 ························································· 12
欧盟拟采取措施降低 Tysabri 的脑部感染PML 风险······························································· 13
日本更新氨氯地平的安全性信息······························································································ 14
日本提示伊曲康唑的间质性肺炎的风险·················································································· 15
日本提示哌拉西林钠的急性全身发疹性脓疱病风险······························································· 15
加拿大警示哌拉西林的药物超敏反应综合征 ·········································································· 15
英国提示厄洛替尼适应证信息的重要变更 ·············································································· 16
英国发布丙戊酸钠与异常妊娠结局风险的最新宣传资料 ······················································· 17
•药物不良反应通报•
警惕注射用单磷酸阿糖腺苷严重不良反应及超适应症用药风险 ··········································· 19
•药事管理•
药物咨询····································································································································· 21
不良反应······················································································
文档评论（0）